Cardiovascular disease continues as the leading cause of death globally, with current therapies primarily targeting the reduction of major adverse cardiovascular events. While LDL-C reducing statins decrease these events by approximately 25%, lipoprotein apheresis devices that filter LDL-C and Lipoprotein(a) from the bloodstream can reduce incidence by 75-95% according to the American Heart Association. However, widespread adoption of these technologies has been limited by complex, multi-component designs lacking global delivery infrastructure.
Sigyn Therapeutics has developed CardioDialysis, which the company describes as the first technology in subtractive medicine to fully integrate plasma separation and therapeutic adsorption within a single device. This innovation enables continuous broad-spectrum clearance of both inflammatory and pathogenic molecules from the entire bloodstream. The device is designed to be deployed on dialysis machines already located in hospitals and clinics, potentially overcoming the infrastructure limitations of existing technologies.
The company contrasts CardioDialysis with the FDA-approved Kaneka LIPOSORBER lipoprotein apheresis procedure, which has administered approximately 600,000 treatments to more than 6,000 patients worldwide. The LIPOSORBER system requires a plasma separation column, two LIPOSORBER cartridges, custom blood tubing sets, a blood warmer, multiple bags of replacement fluids, multiple bags of regeneration fluids, four waste bags, and four different pumps. Due to this complexity, access to LIPOSORBER treatment is limited to fewer than 60 specialized apheresis centers in the United States.
In comparison, CardioDialysis is a fully integrated single-component device deployable on dialysis machines already located in more than 5,000 hospitals and 7,500 dialysis clinics in the United States alone. According to the company, CardioDialysis addresses a broader range of cardiovascular disease targets, processes the bloodstream with greater efficiency, and does not require replacement fluids, additional pumps, or other auxiliary components.
The potential impact of this technology is significant given that 15-20% of major adverse cardiovascular events result in death. The successful clinical advancement of CardioDialysis could save thousands of lives annually by providing more accessible and efficient treatment options. The company's technology represents an approach to overcoming the inherent limitations of single-target drugs in cardiovascular disease treatment by simultaneously reducing inflammatory mediators and cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other major adverse cardiovascular events.
Sigyn Therapeutics' development pipeline includes additional technologies such as ImmunePrep to optimize immunotherapeutic antibody delivery for cancer treatment, ChemoPrep to enhance targeted chemotherapy delivery, and ChemoPure to reduce chemotherapy toxicity. More information about the company is available at https://www.SigynTherapeutics.com. The original press release can be viewed at https://www.newmediawire.com.
